India · Delayed Price · Currency is INR Mankind Pharma Statistics
Total Valuation
Mankind Pharma has a market cap or net worth of INR 984.58 billion. The enterprise value is 1.03 trillion.
| Market Cap | 984.58B |
| Enterprise Value | 1.03T |
Important Dates
The last earnings date was Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 413.00M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.36% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 57.69% |
| Owned by Institutions (%) | 20.75% |
| Float | 112.99M |
Valuation Ratios
The trailing PE ratio is 48.20 and the forward PE ratio is 39.30.
| PE Ratio | 48.20 |
| Forward PE | 39.30 |
| PS Ratio | 6.68 |
| PB Ratio | 5.95 |
| P/TBV Ratio | 590.99 |
| P/FCF Ratio | 39.46 |
| P/OCF Ratio | 31.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.16, with an EV/FCF ratio of 41.21.
| EV / Earnings | 50.34 |
| EV / Sales | 6.98 |
| EV / EBITDA | 26.16 |
| EV / EBIT | 33.89 |
| EV / FCF | 41.21 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.38 |
| Debt / EBITDA | 1.61 |
| Debt / FCF | 2.53 |
| Interest Coverage | 5.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 11.80% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.21M |
| Profits Per Employee | 998,812 |
| Employee Count | 20,451 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Mankind Pharma has paid 4.94 billion in taxes.
| Income Tax | 4.94B |
| Effective Tax Rate | 19.29% |
Stock Price Statistics
The stock price has decreased by -5.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -5.33% |
| 50-Day Moving Average | 2,479.33 |
| 200-Day Moving Average | 2,275.18 |
| Relative Strength Index (RSI) | 33.74 |
| Average Volume (20 Days) | 45,501 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mankind Pharma had revenue of INR 147.38 billion and earned 20.43 billion in profits. Earnings per share was 49.42.
| Revenue | 147.38B |
| Gross Profit | 104.29B |
| Operating Income | 30.22B |
| Pretax Income | 25.62B |
| Net Income | 20.43B |
| EBITDA | 38.90B |
| EBIT | 30.22B |
| Earnings Per Share (EPS) | 49.42 |
Balance Sheet
The company has 22.08 billion in cash and 63.12 billion in debt, with a net cash position of -41.04 billion.
| Cash & Cash Equivalents | 22.08B |
| Total Debt | 63.12B |
| Net Cash | -41.04B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 165.61B |
| Book Value Per Share | 394.85 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 31.21 billion and capital expenditures -6.26 billion, giving a free cash flow of 24.95 billion.
| Operating Cash Flow | 31.21B |
| Capital Expenditures | -6.26B |
| Depreciation & Amortization | 8.68B |
| Net Borrowing | -22.64B |
| Free Cash Flow | 24.95B |
| FCF Per Share | n/a |
Margins
Gross margin is 70.76%, with operating and profit margins of 20.50% and 13.86%.
| Gross Margin | 70.76% |
| Operating Margin | 20.50% |
| Pretax Margin | 17.38% |
| Profit Margin | 13.86% |
| EBITDA Margin | 26.39% |
| EBIT Margin | 20.50% |
| FCF Margin | 17.48% |
Dividends & Yields
Mankind Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.36% |
| Shareholder Yield | -1.36% |
| Earnings Yield | 2.07% |
| FCF Yield | 2.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Mankind Pharma is 2,741.74, which is 15.59% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,741.74 |
| Price Target Difference | 15.59% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 11.83% |
| EPS Growth Forecast (3Y) | 17.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |